Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncolytics Bio (ONC.TO)

Oncolytics Bio (ONC.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oncolytics Bio 322 11th Avenue S.W Suite 804 Calgary AB T2R 0C5 CAN

https://www.oncolyticsbiotech.com P: 403-670-7377 F: 403-283-0858

Description:

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

Key Statistics

Overview:

Market Capitalization, $K 106,063
Shares Outstanding, K 76,857
Annual Sales, $ 0 K
Annual Net Income, $ -27,752 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -9,543 K
60-Month Beta 1.28
% of Institutional Shareholders 0.09%

Growth:

1-Year Return -32.04%
3-Year Return -36.99%
5-Year Return 2.22%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.12 on 11/12/24
Next Earnings Date N/A
Earnings Per Share ttm -0.36
EPS Growth vs. Prev Year -29.41%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 05/25/18

ONC.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -145.20%
Return-on-Assets % -78.58%
Profit Margin % 0.00%
Debt/Equity 0.01
Price/Sales N/A
Price/Book 11.71
Book Value/Share 0.12
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar